As of 2026-04-17, the EV/EBITDA ratio of Travere Therapeutics Inc (TVTX) is 312.78. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TVTX's latest enterprise value is 2,971.14 mil USD. TVTX's TTM EBITDA according to its financial statements is 9.50 mil USD. Dividing these 2 quantities gives us the above TVTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative Enterprise Value.
| Range | Selected | |
| Trailing P/E multiples | 8.8x - 14.7x | 11.8x |
| Forward P/E multiples | 11.2x - 17.6x | 14.9x |
| Fair Price | (2.00) - 0.59 | (0.79) |
| Upside | -104.9% - -98.6% | -101.9% |
| Date | EV/EBITDA |
| 2026-04-10 | 227.94 |
| 2026-04-09 | 245.49 |
| 2026-04-08 | 247.19 |
| 2026-04-07 | 247.12 |
| 2026-04-06 | 248.25 |
| 2026-04-02 | 238.42 |
| 2026-04-01 | 245.35 |
| 2026-03-31 | 233.25 |
| 2026-03-30 | 218.74 |
| 2026-03-27 | 215.84 |
| 2026-03-26 | 220.58 |
| 2026-03-25 | 218.04 |
| 2026-03-24 | 212.59 |
| 2026-03-23 | 219.38 |
| 2026-03-20 | 212.94 |
| 2026-03-19 | 219.17 |
| 2026-03-18 | 213.79 |
| 2026-03-17 | 219.45 |
| 2026-03-16 | 221.36 |
| 2026-03-13 | 219.74 |
| 2026-03-12 | 217.97 |
| 2026-03-11 | 224.48 |
| 2026-03-10 | 225.61 |
| 2026-03-09 | 228.09 |
| 2026-03-06 | 215.77 |
| 2026-03-05 | 216.27 |
| 2026-03-04 | 222.42 |
| 2026-03-03 | 223.06 |
| 2026-03-02 | 231.98 |
| 2026-02-27 | 233.82 |
| 2026-02-26 | 233.32 |
| 2026-02-25 | 230.63 |
| 2026-02-24 | 241.53 |
| 2026-02-23 | 240.47 |
| 2026-02-20 | 238.06 |
| 2026-02-19 | 230.35 |
| 2026-02-18 | 220.23 |
| 2026-02-17 | 226.46 |
| 2026-02-13 | 219.88 |
| 2026-02-12 | 239.55 |
| 2026-02-11 | 236.86 |
| 2026-02-10 | 237.57 |
| 2026-02-09 | 235.80 |
| 2026-02-06 | 233.25 |
| 2026-02-05 | 231.55 |
| 2026-02-04 | 247.19 |
| 2026-02-03 | 255.40 |
| 2026-02-02 | 257.20 |
| 2026-01-30 | 243.02 |
| 2026-01-29 | 249.38 |